Ou, Yang
Eli Lilly (United States)
3 papers on CoChatORCID 0009-0004-5020-7912
Most cited papers
- Verified
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology
Cardiovascular Disease and AdiposityHeart Failure Treatment and Management
Cited by 200
- Verified
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 74
- Verified
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology
Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 49
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free